A potential protective role of losartan against coronavirus-induced lung damage
Open Access
- 17 March 2020
- journal article
- letter
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 41 (6) , 752-753
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The effects of losartan on cytomegalovirus infection in human trabecular meshwork cellsPLOS ONE, 2019
- Angiotensin II type 1 receptor blocker losartan attenuates locomotor, anxiety-like behavior, and passive avoidance learning deficits in a sub-chronic stress model2018
- Inhibition of Marfan Syndrome Aortic Root Dilation by LosartanThe American Journal of Pathology, 2018
- The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosisJournal of Lung, Pulmonary & Respiratory Research, 2018
- Losartan may inhibit the progression of liver fibrosis in chronic HCV patientsHepatoBiliary Surgery and Nutrition, 2016
- Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injuryScientific Reports, 2014
- Losartan attenuates paraquat-induced pulmonary fibrosis in ratsHuman & Experimental Toxicology, 2014
- Angiotensin-Converting Enzyme 2: The First DecadeInternational Journal of Hypertension, 2011
- Renin–Angiotensin System in Human Coronavirus PathogenesisFuture Virology, 2010
- Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetesJACC, 2000